Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00389324 · ClinicalTrials.gov registry record · Phase 2
A Trial of the Pharmacokinetics, Safety, and Tolerability of Subcutaneous Gamunex® in Primary Immunodeficiency
A Phase 2 study, sponsored by Grifols Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT00389324 is a Phase 2 study that has completed, run by Grifols Therapeutics. The registered enrollment target is 35 participants.
The verdict
NCT00389324, a Phase 2 study, has completed, sponsored by Grifols Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
This study will compare the blood level of Gamunex in patients. Patients will take it as an injection under the skin or in a vein. The study will compare how safe and tolerable the two methods are in the patients. The patients in this study have a defect in their immune system from a genetic cause.
Interventions
- BIOLOGICAL Immune Globulin Intravenous (Human)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2006-11 |
| Est. Completion | 2008-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00389324
The ClinicalTrials.gov registry entry for NCT00389324 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Grifols Therapeutics, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Immune Globulin Intravenous (Human) is the first listed.
NCT00389324 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00389324 about?
NCT00389324 is a clinical study titled "A Trial of the Pharmacokinetics, Safety, and Tolerability of Subcutaneous Gamunex® in Primary Immunodeficiency". This study will compare the blood level of Gamunex in patients. Patients will take it as an injection under the skin or in a vein. The study will compare how safe and tolerable the two methods are in the patients. The patients in this study have a defect in their immune system from a genetic cause.
What is the current status of trial NCT00389324?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2006-11. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00389324?
The interventions under investigation include: Immune Globulin Intravenous (Human) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00389324?
This trial is sponsored by Grifols Therapeutics, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.